Maternal SSRI use during pregnancy may be associated with altered brain development in children; however, this study cannot fully rule out contributions of confounding genetic and enviromental factors.
Analyzing data from nearly 150,000 children with prenatal antidepressant exposure in two healthcare databases, a recent study finds no association between prenatal exposure to antidepressants and risk for neurodevelopmental disorders.
While questions and controversies remain, the information on long-term neurodevelopmental outcomes in children prenatally exposed to antidepressants is largely reassuring.
Prozac (fluoxetine) was the first SSRI or selective serotonin reuptake inhibitor. Since its release in 1988, we have been gathering data on the reproductive safety of fluoxetine and other SSRIs. Over the last 32 years, [...]
We have long been interested in understanding the effects of prenatal exposure to antidepressants on the development of the fetal brain. The earliest studies addressing this question were small but yielded detailed (and reassuring) information [...]
It was back in 2005 when we first reported on studies which demonstrated an increased risk of “poor neonatal adaptation” in infants with prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants in late pregnancy. [...]
